Adjuvant therapy in the treatment of non-small-cell lung cancer

Anne M. Traynor; Joan H. Schiller

doi:10.3816/CLC.2002.n.023

Adjuvant therapy in the treatment of non-small-cell lung cancer

Anne M. Traynor, Joan H. Schiller

Internal Medicine

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Randomized trials to date have not consistently demonstrated a benefit in overall survival with the use of adjuvant chemotherapy, radiotherapy, or combined modality chemoradiation in patients with resected non-small-cell lung cancer. Subset analyses suggest a reduction in local relapse with adjuvant radiotherapy for patients with completely resected N2 disease. Improvements in patient selection and treatment plans are urgently needed.

Original language	English (US)
Pages (from-to)	161-167
Number of pages	7
Journal	Clinical lung cancer
Volume	4
Issue number	3
DOIs	https://doi.org/10.3816/CLC.2002.n.023
State	Published - Nov 2002

Keywords

Chemotherapy
Postoperative period
Radiotherapy
Surgery

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.3816/CLC.2002.n.023

Cite this

@article{4d7f2f65d83449a3a4aeabd907462c54,

title = "Adjuvant therapy in the treatment of non-small-cell lung cancer",

abstract = "Randomized trials to date have not consistently demonstrated a benefit in overall survival with the use of adjuvant chemotherapy, radiotherapy, or combined modality chemoradiation in patients with resected non-small-cell lung cancer. Subset analyses suggest a reduction in local relapse with adjuvant radiotherapy for patients with completely resected N2 disease. Improvements in patient selection and treatment plans are urgently needed.",

keywords = "Chemotherapy, Postoperative period, Radiotherapy, Surgery",

author = "Traynor, {Anne M.} and Schiller, {Joan H.}",

note = "Funding Information: Stephens and colleagues from the Medical Research Council investigated the role of postoperative radiotherapy in the T1-2 N1-2 setting by randomizing 308 patients to 40 Gy radiation in 2.67 Gy fractions or observation.21 No benefit in OS or in suspected or definite local relapse was seen with radiation treatments for the study population as a whole. However, subgroup analyses of the 106 patients with N2 disease revealed a reduction in the incidence of local and distant (bones and brain) recurrence for the irradiated patients.",

year = "2002",

month = nov,

doi = "10.3816/CLC.2002.n.023",

language = "English (US)",

volume = "4",

pages = "161--167",

journal = "Clinical lung cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Adjuvant therapy in the treatment of non-small-cell lung cancer

AU - Traynor, Anne M.

AU - Schiller, Joan H.

N1 - Funding Information: Stephens and colleagues from the Medical Research Council investigated the role of postoperative radiotherapy in the T1-2 N1-2 setting by randomizing 308 patients to 40 Gy radiation in 2.67 Gy fractions or observation.21 No benefit in OS or in suspected or definite local relapse was seen with radiation treatments for the study population as a whole. However, subgroup analyses of the 106 patients with N2 disease revealed a reduction in the incidence of local and distant (bones and brain) recurrence for the irradiated patients.

PY - 2002/11

Y1 - 2002/11

N2 - Randomized trials to date have not consistently demonstrated a benefit in overall survival with the use of adjuvant chemotherapy, radiotherapy, or combined modality chemoradiation in patients with resected non-small-cell lung cancer. Subset analyses suggest a reduction in local relapse with adjuvant radiotherapy for patients with completely resected N2 disease. Improvements in patient selection and treatment plans are urgently needed.

AB - Randomized trials to date have not consistently demonstrated a benefit in overall survival with the use of adjuvant chemotherapy, radiotherapy, or combined modality chemoradiation in patients with resected non-small-cell lung cancer. Subset analyses suggest a reduction in local relapse with adjuvant radiotherapy for patients with completely resected N2 disease. Improvements in patient selection and treatment plans are urgently needed.

KW - Chemotherapy

KW - Postoperative period

KW - Radiotherapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=0036868673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036868673&partnerID=8YFLogxK

U2 - 10.3816/CLC.2002.n.023

DO - 10.3816/CLC.2002.n.023

M3 - Review article

C2 - 14706165

AN - SCOPUS:0036868673

SN - 1525-7304

VL - 4

SP - 161

EP - 167

JO - Clinical lung cancer

JF - Clinical lung cancer

IS - 3

ER -

Adjuvant therapy in the treatment of non-small-cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this